Literature DB >> 11739020

The vasorelaxant hormone relaxin induces changes in liver sinusoid microcirculation: a morphologic study in the rat.

D Bani1, S Nistri, S Quattrone, M Bigazzi, T Bani Sacchi.   

Abstract

This study shows that specialized contractile endothelial cells exist in rat liver sinusoids which may be involved in the local control of hemodynamics and which are sensitive to vasoactive agents, including the vasorelaxant hormone relaxin. Male rats were treated with 10 microg relaxin for 4 days; phosphate-buffered saline (PBS)-treated rats were the controls. For comparison, rats treated with relaxin together with the NO-synthase inhibitor N(omega)-nitro-l -arginine methyl ester (L-NAME), and rats treated with the vasodilator taurodeoxycholic acid or the vasoconstrictor ethanol were investigated. Liver fragments were studied morphologically and morphometrically. In the control rats, peculiar contractile cells were present in the endothelial lining. These cells had abundant myofilaments and formed cytoplasmic blebs projecting into and often occluding the lumen. In the ethanol-treated rats, sinusoids were constricted and filled with cytoplasmic blebs. In the relaxin-treated rats, sinusoids were markedly dilated and the cytoplasmic blebs nearly disappeared. Similar findings were observed in the taurodeoxycholic acid-treated rats. The effects of relaxin were blunted by L-NAME, suggesting that the relaxin action involves an NO-mediated mechanism.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11739020     DOI: 10.1677/joe.0.1710541

Source DB:  PubMed          Journal:  J Endocrinol        ISSN: 0022-0795            Impact factor:   4.286


  12 in total

1.  Serelaxin induces Notch1 signaling and alleviates hepatocellular damage in orthotopic liver transplantation.

Authors:  Shoichi Kageyama; Kojiro Nakamura; Bibo Ke; Ronald W Busuttil; Jerzy W Kupiec-Weglinski
Journal:  Am J Transplant       Date:  2018-03-23       Impact factor: 8.086

2.  Recombinant relaxin protects liver transplants from ischemia damage by hepatocyte glucocorticoid receptor: From bench-to-bedside.

Authors:  Shoichi Kageyama; Kojiro Nakamura; Takehiro Fujii; Bibo Ke; Rebecca A Sosa; Elaine F Reed; Nakul Datta; Ali Zarrinpar; Ronald W Busuttil; Jerzy W Kupiec-Weglinski
Journal:  Hepatology       Date:  2018-05-10       Impact factor: 17.425

3.  Enhanced serelaxin signalling in co-cultures of human primary endothelial and smooth muscle cells.

Authors:  M Sarwar; C S Samuel; R A Bathgate; D R Stewart; R J Summers
Journal:  Br J Pharmacol       Date:  2016-01-15       Impact factor: 8.739

4.  Hepatoprotective effects of the nitric oxide donor isosorbide-5-mononitrate alone and in combination with the natural hepatoprotectant, silymarin, on carbon tetrachloride-induced hepatic injury in rats.

Authors:  Omar Mohamed E Abdel Salam; Amany A Sleem; Nermeen Shafee
Journal:  Inflammopharmacology       Date:  2010-01-14       Impact factor: 4.473

Review 5.  Anti-fibrotic actions of relaxin.

Authors:  C S Samuel; S G Royce; T D Hewitson; K M Denton; T E Cooney; R G Bennett
Journal:  Br J Pharmacol       Date:  2016-07-07       Impact factor: 8.739

Review 6.  G-Protein-coupled receptors as potential drug candidates in preeclampsia: targeting the relaxin/insulin-like family peptide receptor 1 for treatment and prevention.

Authors:  Kirk P Conrad
Journal:  Hum Reprod Update       Date:  2016-07-06       Impact factor: 15.610

Review 7.  Relaxin and its role in the development and treatment of fibrosis.

Authors:  Robert G Bennett
Journal:  Transl Res       Date:  2009-04-22       Impact factor: 7.012

8.  Relaxin inhibits cardiac fibrosis and endothelial-mesenchymal transition via the Notch pathway.

Authors:  X Zhou; X Chen; J J Cai; L Z Chen; Y S Gong; L X Wang; Z Gao; H Q Zhang; W J Huang; H Zhou
Journal:  Drug Des Devel Ther       Date:  2015-08-11       Impact factor: 4.162

Review 9.  Relaxin as a natural agent for vascular health.

Authors:  Daniele Bani
Journal:  Vasc Health Risk Manag       Date:  2008

Review 10.  Relaxin-2 in Cardiometabolic Diseases: Mechanisms of Action and Future Perspectives.

Authors:  Sandra Feijóo-Bandín; Alana Aragón-Herrera; Diego Rodríguez-Penas; Manuel Portolés; Esther Roselló-Lletí; Miguel Rivera; José R González-Juanatey; Francisca Lago
Journal:  Front Physiol       Date:  2017-08-18       Impact factor: 4.566

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.